Foxhollow seeks renewal of Merck contract

By Elaine Rigoli

Tampa, Fla., Sept. 19 - Foxhollow Technologies, Inc.'s collaboration and license agreement with Merck & Co., Inc. ended without being renewed, Foxhollow said in an 8-K filing with the Securities and Exchange Commission.

The company noted that it is in discussions with Merck regarding the renewal and extension of the collaboration.

The Redwood City, Calif.-based medical technology company said this collaboration relates to the analysis of atherosclerotic plaque removed from patient arteries with the objective of identifying new biomarkers of atherosclerotic disease progression.

Under the collaboration, the research program described in the agreement terminated on Sept. 15.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.